Overview

Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

Status:
Recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.

Phase:

Phase 4

Details

Lead Sponsor:

Shinshu University

Treatments:

Denosumab
Teriparatide